| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA485: Sarilumab for moderate to severe rheumatoid arthritis |
|
Medicine details |
|
| Medicine name | sarilumab (Kevzara®) |
| Formulation | subcutaneous injection |
| Reference number | 699 |
| Indication | In combination with methotrexate (MTX) for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Kevzara can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate |
| Company | Sanofi-Aventis Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 25/02/2017 |
| NICE guidance | TA485: Sarilumab for moderate to severe rheumatoid arthritis |